since the initial approval of iclusig in europe in 2013, we have over 10 years of experience in treating patients with cml
Click on the short videos below to see how far we’ve come and learn why the experts think you should
consider switching eligible patients with CML* to ICLUSIG after one 2G TKI...
Valentín García-Gutiérrez
Servicio de Hematología
Hospital Universitario Ramón y Cajal (IRYCIS)
Madrid, Spain
Before the discovery of ICLUSIG, treatment failure in CML was devastating for patients1–3
Valentín García-Gutiérrez Disclosures
Company/Organisation
Relationship(s)
Novartis, BMS, Incyte, Pfizer
Travel grants, research funding, advisory board
Simona Soverini
Institute of Hematology
‘L. & A. Seràgnoli’
University of Bologna
Bologna, Italy
ICLUSIG became the first and
remains the only pan-inhibitor of BCR::ABL1
approved for CML in Europe, collectively suppressing all single point mutations
(including T315I)4,5
Simona Soverini Disclosures
Company/Organisation
Relationship(s)
Incyte
Consultancy
Jane Apperley
Centre for Haematology
Hammersmith Hospital
Imperial College London
London, UK
ICLUSIG has been with you since 2013,
proudly demonstrating fast, deep and durable responses
as seen in the long-term follow-up of the PACE study5,6
Jane Apperley Disclosures
Company/Organisation
Relationship(s)
Incyte, Novartis, Paladin Labs
Speaker
Incyte, Novartis
Advisory boards
BMS, Incyte, Novartis, Pfizer
Research funding
Jorge Cortes
Georgia Cancer Center
Augusta, GA, USA
Thanks to the recent response-based dosing study, OPTIC,
there’s now clear evidence to induce, reduce and maintain ICLUSIG to manage your patients7
Induce response with 45 mg orally, once daily; reduce dose to 15 mg orally, once daily, upon
achievement of ≤1% BCR::ABL1; maintain response with 15 mg orally, once daily.
Jorge Cortes Disclosures
Company/Organisation
Relationship(s)
BMS, Novartis, Pfizer, Takeda, Sun Pharma, Incyte
Consultant
BMS, Novartis, Pfizer, Takeda, Sun Pharma
Research support
ICLUSIG: COMMITMENT TO BUILDING PATIENTS' FUTURES
You are now leaving the site www.iclusig.se.
This link will take you to a site https://www.incyte.com, owned by Incyte Corporation and managed
by the company.